Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2012) 29 P1825

Centro Nacional de Investigaciones Oncoló gicas, Madrid, Spain.


Papillary thyroid cancer (PTC) is the most common endocrine malignancy. Its management has not changed significantly in recent decades, and most patients receive the same treatment. Moreover, there are not alternative treatments for low response or aggressive neoplasias. The availability of reliable prognostic markers that would allow the PTC to be identified based on their aggressiveness at the time of diagnosis would derive in an individualized treatment. In a previous study, our group identified a transcript profile by DNA microarray that allows a prognostic classification with an accuracy level of 95% over its evolution. The current study aimed to establish an immunohistochemical profile to help determine the prognosis of evolution of the PTC

Materials and methods: We have performed Tissue Microarrays immunohistochemistry in a large series of 184 cases of PTC, clinically well characterized, with 17 antibodies (Ab) against proteins encoded by some of the genes identified in our previous study. For statistical analysis, we used the intra-individual mean obtained from four experimental replicates to measure Ab expression. We used the Mann-Whitney U to compare the values of the histoscore group as defined by the prognosis, and adjusted logistic regression model to identify those that contribute significantly to explain tumor poor prognosis

Results: Preliminary analysis of the samples showed differences between groups defined according to forecasts for 12 Ab. The multivariate logistic regression model to explain and distinguish poor from good prognosis showed that five Ab achieved an area under the curve of 0.85 [0.79, 0.90] and an optimal cut-off levels of sensitivity of 90% and specificity of 59%

Conclusions: The preliminary results provide promising results for differentiating good and poor prognosis of PTC. The combination of Ab identified may contribute to the prognostic stratification of PTC (with potential clinical applications)

Fx1

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This work was supported, however funding details unavailable.

/media/12612/414961g1.gif

Volume 29

15th International & 14th European Congress of Endocrinology

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.